Highest-materiality recent filing
Immunic shareholders approve 6M share increase to equity plan, elect directors, ratify auditor
Amendment to 2019 Omnibus Equity Plan approved, increasing authorized shares by 6,000,000 to total 8,644,887.
Late-breaking poster introduces novel unified endpoint Confirmed Disability Change (CDC) that consistently favored vidofludimus calcium over placebo across three statistical models.
Immunic appoints Erik Lundgren as CEO; Daniel Vitt resigns as CEO but remains on board
Erik Lundgren appointed CEO effective June 1, 2026; previously SVP at Genentech/Roche, led Ocrevus launch.
Immunic appoints Michael W. Bonney as Chair of Board; MS expertise ahead of trial readouts
Michael W. Bonney appointed Chair effective May 16, 2026; Simona Skerjanec transitions from Interim Chair to board member.
Immunic reports Q1 net loss $32.6M; cash $186.6M; Phase 3 MS data by end-2026
Net loss $32.6M ($1.08/share) vs $25.5M ($2.51/share) YoY; R&D expenses $25.6M.
Michael Panzara appointed CMO effective April 24, 2026; base salary $600K, annual bonus target ≥50% of salary, signing bonus $125K.
Immunic stockholder votes authorize reverse split at 1-for-10, effective April 27, 2026
Stockholders approved reverse stock split with 57.4M votes for, 12.6M against, 0.6M abstentions.
Immunic CEO Daniel Vitt enters $670,000 retention bonus as board searches for new CEO
Retention bonus of $670,000 payable if Vitt remains employed through 91st day after new CEO hired.
Immunic closes $200M private placement; CEO Vitt to transition; Phase 3 MS data by end-2026
Closed oversubscribed private placement of up to $400M; $200M gross proceeds received Feb 17, 2026.
Immunic announces up to $400M private placement and board changes to fund MS trials
Gross proceeds of up to $400M from private placement led by BVF Partners, with $200M from pre-funded warrants at $0.873 each.
Received approval on Jan 5, 2026 to transfer listing from Nasdaq Global Select to Capital Market, effective Jan 7, 2026.
Immunic Q3 2025 net loss $25.6M; cash $35.1M; warns insufficient liquidity for 12 months
Net loss of $25.6M ($0.13/share) vs $24.4M ($0.24/share) in Q3 2024; nine-month loss $77.9M.
Vidofludimus calcium achieved statistically significant 24-week confirmed disability improvement (HR 2.441, p=0.034) in Phase 2 CALLIPER trial in progressive multiple sclerosis.
Immunic Q2 net loss $27M; vidofludimus reduces disability worsening 24% in PMS trial
Net loss of $27.0M ($0.20/share) for Q2 2025 vs $21.4M ($0.21/share) in Q2 2024.
Immunic receives Nasdaq notice for non-compliance with $1.00 minimum bid price
On June 27, 2025, Nasdaq notified Immunic that its common stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
Immunic prices $65M underwritten offering of pre-funded warrants and Series A/B warrants
Offering of 86.7M pre-funded warrants plus Series A & B warrants at $0.7499 per unit; proceeds ~$65M.
Vidofludimus calcium reduced 24-week confirmed disability worsening risk by 20% overall (n=467) vs placebo.
Immunic prices $5.1M registered direct offering of 5.67M shares at $0.90/share
Offering led by Aberdeen Investments; Titan Partners as placement agent.
Immunic's IMU-856 shows dose-dependent GLP-1 increase in celiac trial; preclinical weight loss
Post-hoc phase 1b analysis: dose-dependent GLP-1 increase up to 250% vs placebo; p=0.014 (80mg) and p=0.003 (160mg).
Immunic Q3 net loss $24.4M; positive ENSURE futility analysis; cash runway into Q3 2025
Net loss Q3 2024: $24.4M ($0.24/share) vs $22.8M ($0.51/share) in Q3 2023.
IDMC recommended ENSURE-1 and ENSURE-2 continue unchanged; predetermined futility criteria not met.
Immunic Q2 net loss $21.4M ($0.21/shr); appoints COO/President Tardio, Board member Skerjanec
Net loss of $21.4M for Q2 2024 vs $24.0M Q2 2023; diluted EPS -$0.21 on 101.3M shares.
Immunic appoints Jason Tardio as COO/President and promotes Werner Gladdines to CDO
Jason Tardio, former Novartis MS franchise head and Biogen exec, appointed COO and President effective July 12, 2024.
Immunic reports Q1 2024 net loss $29.6M; cash extended into Q3 2025 on $240M private placement
Net loss $29.6M ($0.30/share) vs $25.3M ($0.58) in Q1 2023; R&D spend $18.7M, down 18% YoY.
Immunic reports FY2023 net loss of $93.6M; raises $80M in Jan 2024 private placement
Net loss for FY2023: $93.6M ($2.11 per share) vs $120.4M ($3.78 per share) in FY2022.
Immunic announces private placement of up to $240M; first $80M tranche closes Jan 8
First tranche $80M at $1.43/share to close Jan 8, 2024; lead investor BVF Partners.
Immunic reports Q3 2023 net loss $22.8M; positive CALLIPER interim NfL data
Net loss of $22.8M ($0.51/sh) for Q3 2023 vs $21.2M ($0.69/sh) in Q3 2022.
Immunic reports positive Phase 2 CALLIPER interim data: NfL reduced 22.4% vs placebo in PMS
Vidofludimus calcium lowered serum NfL by 22.4% vs placebo at 24 weeks in overall PMS (p=0.01 post hoc).
Immunic Q1 net loss $25.3M; positive phase 1b IMU-856 celiac data; cash $97.1M
Q1 net loss $25.3M ($0.58/sh) vs $20.8M ($0.74/sh); R&D expenses $23.0M up from $17.4M YoY.
Placebo group had 60.3 µm villous height reduction vs. 20.9 µm (80mg) and 22.5 µm (160mg) for IMU-856 (p=0.04) under gluten challenge.
On May 22, 2026 (the “Effective Date”), Immunic, Inc. (the "Company") appointed Erik Lundgren, as Chief Executive Officer of the Company, with his start of employment beginning on June 1, 2026.
Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.
appointed Michael W. Bonney as Chair of the Board, effective immediately.
Immunic, Inc. (the "Company") appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer of the Company, effective immediately.
On July 24, 2024, Immunic, Inc. (the “Company”) announced the appointment of Simona Skerjanec, M.Pharm, MBA, as a member of the board of directors (the “Board”) of the Company, effective as of July 22, 2024.
appointment of Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.
promotion of Werner Gladdines from Vice President, Program Management & Clinical Development Operations to Chief Development Officer of the Company.
Additionally, on April 26, 2023, Dr. Vincent Ossipow notified the Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting.
On April 27, 2023, Immunic, Inc. (the “Company”) announced the appointment of Dr. Richard Rudick as a member of the Board of Directors (the “Board”) of the Company, effective as of April 26, 2023.
On July 5, 2022, Immunic, Inc. (the “Company”) announced the appointment of Monika Maria Törnsén as a member of the Board of Directors (the “Board”) of the Company, effective as of July 5, 2022.
The Company also announced that current Class III director, Jan Van den Bossche, will be resigning from the Board. The Board accepted Mr. Van den Bossche’s resignation effective July 5, 2022.
On March 10, 2022, Glenn Whaley was appointed Chief Financial Officer ("CFO") of the Company.
Max materiality 0.95 · Median 0.65 · Most common event other_material